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An appraisal of antiretroviral drugs in hemodialysis. HEMODIALYSIS AND DRUG ELIMINATION
Background. Acquired immunodeficiency syndrome (AIDS)-
Dialysis therapy is used in chronic uremia to removerelated kidney disorders concern 30% of those patients and can
toxic waste products that accumulate in patients withlead to end-stage renal disease (ESRD; 6 to 10%). Therefore,
the administration of antiretroviral drugs in human immunodefi- ESRD. However, this technique also removes drugs as
ciency virus (HIV) patients with nephropathy is not uncommon. well as waste. Therefore, it is necessary to determine
Methods. The influence of ESRD on the different phases of the removed fraction of drugs during the procedure by
the pharmacokinetic profile of drugs in general is examined in
hemodialysis clearance, extraction coefficient, and he-light of bioavailability, distribution, protein binding, metabo-
modialysis elimination of the absorbed dose (FHD).lism, and elimination. Then, the pharmacokinetics of antiret-
roviral drugs in hemodialysis are detailed.
Hemodialysis clearanceResults. From these data, dosing recommendations are given
for nucleoside reverse transcriptase inhibitors (NRTIs), non- Dialysis clearance is the rate of removal relative to
NRTIs, and protease inhibitors (PIs).
the concentration in the blood entering the dialyzer. ItConclusion. Dosage adjustments are often necessary for pa-
is calculated by the amount removed (mg/min) relativetients with renal insufficiency. These adaptations have to be
carefully performed to optimize drug exposure and reduce the to the rate of presentation (mg/mL).
risk of side effects.
CHD (mL/min)  [(Ca  Cv)  Qb]/Ca
where CHD is the hemodialysis (HD) clearance, Ca is the
Renal insufficiency is common in human immuno- concentration entering the dialyzer (mg/mL), Cv is the
deficiency virus (HIV)-infected patients (6 to 10%) [1, 2]. concentration leaving the dialyzer (mg/mL), and Qb is
HIV-associated nephropathy (HIVAN) and other ac- the blood flow (mL/min).
quired immunodeficiency syndrome (AIDS)-related kid-
Extraction coefficientney disorders are expected to become leading causes
of end-stage renal disease (ESRD). Nucleoside reverse The extraction coefficient (E), also called the extrac-
transcriptase inhibitors (NRTIs) used in HIV therapy tion ratio, is the percentage of a drug removed from
are primarily excreted by the kidney. Furthermore, they blood across the dialyzer. It is calculated by the rate of
are most often used in combination: two NRTIs plus one removal (mL/min) relative to the rate of presentation
protease inhibitor (PI) or two NRTIs plus one non-NRTI. (mL/min).
Therefore, clinicians need to understand the pharmaco-
E (%)  CHD/Qbkinetic disposition of these compounds in patients with
renal impairment. where CHD is the hemodialysis clearance (removal; mL/
This article reviews the impact of hemodialysis on the min), and Qb is the blood flow rate (mL/min).
pharmacokinetics of the antiretroviral drugs used in HIV Dialysis clearance and extraction coefficient measure
disease and discusses the dosage recommendations needed the ability of a dialysis system to remove a drug from
to achieve efficacy while avoiding toxicity in patients the blood. Nevertheless, they do not indicate how readily
with ESRD undergoing hemodialysis. the drug is removed from the body [3].
Drug administration in hemodialysis patients
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of dialysis: V*C0. The second existing approach would of the drug to the dialysis membrane. Therefore, drug
be more accurate and consists of restoring the concentra- removal by dialysis is insignificant for agents with large
tion of the drug at the end of the dialysis session to the Vd values. Protein binding may help determine where a
value that would have occurred if the patient had not drug is distributed once in the body. The degree of pro-
been dialyzed. The amount in body without dialysis can tein binding of a drug also has a significant impact on
be estimated with V*C0*exp(k*t), with k being the its pharmacological effects. Patients with renal disease
elimination rate of the drug without dialysis. The amount exhibit less protein binding of various drugs than subjects
in the body after the dialysis session can be estimated with normal renal function. Qualitative [6] and quantita-
with V*C0*exp(kD*T), with kD being the elimination tive [7] changes in the albumin level of uremic subjects
rate of the drug during the session. Then, the supplemen- explain these observations.
tary dose can be estimated with V*C0*[exp(k*T)  Elimination. Elimination is the irreversible loss of
exp(kD*T)]. drug from the site of measurement (blood, plasma, etc.).
Very often, these data are not available to the clinician. It occurs by two processes: excretion and metabolism [8].
However, the influence of dialysis may be derived from In renal impairment, a drug usually cleared by renal
total body clearance (Ctot) and hemodialysis clearance mechanisms will have a longer half-life (T1⁄2) and an in-
(CHD). Hemodialysis elimination of the absorbed dose creased Vd.
(FHD) is assumed to be clinically relevant if more than Metabolism. Metabolism is the conversion of one chemi-
25% of the overall elimination of a drug in a hemodia- cal species to another [8]. Generally, drugs that undergo
lyzed patient is by this route [4]: FHD  CHD/Ctot. Since hepatic metabolism by microsomal oxidation have simi-
this is a quite recent concept, FHD was not reported in lar elimination profiles in patients with normal and im-
these studies, so we calculated it from data on CHD and paired renal function [9].
Ctot found in the text of these studies. Ctot consists of Excretion. Excretion is the irreversible loss of a chem-
the sum of hemodialysis clearance (CHD) and total body ically unchanged drug [8]. In dialysis patients, renal ex-
clearance derived from the pharmacokinetic analysis on cretion and drug removal by the kidney are replaced
a non-hemodialysis day (CtotNHDD). As a result, FHD  by dialysis. Drugs normally eliminated via glomerular
CHD/(CHD  CtotNHDD). Most of the time, those data were filtration will be at least partially dialyzable. Other drugs,available. To assess FHD, Ctot and CHD must be calculated normally eliminated via tubular secretion, may or mayon a nondialysis day and during dialysis, respectively. FHD not be dialyzable, depending on their molecular weight.is reported as unknown when those data were lacking.
It must be emphasized that hemodialysis clearance Drug properties affecting dialyzability
and the extraction ratio (without FHD) do not allow any
Molecular weight. A drug’s molecular weight is a reli-extrapolation to assess which supplemental dose is war-
able predictor of its dialyzability [10]. If a drug cannotranted.
pass through a dialysis membrane pore because of its
physical size, it is not cleared by the dialyzer [11]. Diffu-PHARMACOKINETICS IN HEMODIALYSIS
sive clearance through conventional dialysis membranesIn patients with ESRD, not only elimination, but all
is negligible for molecules larger than 1000 D. Very fewphases of drug pharmacokinetics may be altered.
commonly used drugs are this large. Utilizing conven-
tional low-flux cellulosic membranes, removal of solutesGeneral considerations
greater than 1000 D generally requires ultrafiltration.Bioavailability. Gastric pH is frequently modified in
Depending on the membrane, even during ultrafiltration,uremic patients. Dialysis patients have an increased sali-
molecules greater than 2000 D are partially reflected byvary urea concentration that is converted into ammonia
the membrane [12].by gastric ureases. Drugs requiring an acid environment
Protein binding and Vd. For drugs characterized byfor optimal absorption may thus exhibit a decreased ab-
high protein binding, only a small proportion of the drugsorption ratio in uremic settings.
is available for removal by dialysis. Heparin administra-Distribution. Uremia alters the apparent volume of
tion during hemodialysis stimulates lipoprotein lipase,distribution (Vd) by various mechanisms. Endogenous
which in turn raises the levels of free fatty acids [13].inhibitors of binding are retained in renal failure and
Free fatty acids may displace or enhance the binding oflead to a larger Vd [5]. Drugs that are minimally bound
drugs. Furthermore, when a drug has a large Vd, it diffusesto plasma proteins have the same Vd in uremia as in
widely in the tissues, and its availability in the circulationsubjects with normal renal function [6]. When systemic
and for the dialyzer is minimal [14]. A comparison ofacidosis is associated with uremia, it allows an increased
drugs with various Vd sizes and same molecular weightsdrug penetration into the central nervous system (CNS).
and protein-bound fractions shows that drugs with a VdThe larger the Vd, the smaller the proportion of drug
remains in circulation and hence the smaller the delivery below 1 L/kg are more readily dialyzed and those with
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a Vd from 1 to 2 L/kg have marginal dialysis clearances; tively) [16, 17]. This is consistent with the physicochemi-
cal and kinetic properties of the drug (molecular weightfor those with a Vd greater than 2 L/kg, substantial drug
removal is unlikely. Despite rapid extracellular solute 1000 D, and low protein-bound fraction and volume
of distribution). ZDV is not significantly removed byclearance with short-time high-flux or high-efficiency di-
alysis, intracellular equilibration with extracellular fluid hemodialysis (FHD 5 to 8%) in contrast with GZDV, the
hemodialysis clearance of which is three to four timescan be slow, especially with larger molecules. This is prob-
ably related to the lipid solubility of the drug and its the residual clearance in nondialyzed uremic patients.
However, in the absence of any data about GZDV activ-tissue compartmentalization. A postdialysis extracellular
rebound usually occurs (10 to 25% variations), but with ity and/or toxicity, it is recommended that the dose
should be administered after the dialysis session to avoidlow influence on intracellular drug concentrations (1 to
2% variations). Higher filtration rates aggravate this re- potential clinically significant removal of the metabolite.
Didanosine. Didanosine (ddI) has a molecular weightbound phenomenon.
Drug-red blood cell binding. Drugs that diffuse in red of 236.23 D, a fraction bound to plasma protein of less
than 5%, and a volume of distribution of 0.8 L/kg. Fiftyblood cells (RBCs) and have a partition coefficient ex-
ceeding one unit may have decreased clearances due to to 55% of each ddI dose is excreted unchanged in the
urine. The nonexcreted fraction is metabolized by thehemoconcentration at the end of dialysis.
Miscellaneous drug properties. Water solubility and liver into hypoxanthine, uric acid, and dideoxyadenosine
triphosphate [17]. Certain changes in the pharmacokinet-electric charge of a drug may affect its dialyzability. It
has been suggested that charged drugs are less dialyzable ics of ddI occur in renal impairment. The area under the
concentration-time curve (AUC) is fourfold to fivefoldthan uncharged. However, the data on real impact of
these properties on drug dialyzability are scanty. greater than in subjects with normal renal function. Dos-
age adjustment is therefore necessary for patients with
renal insufficiency (Table 5). Hemodialysis clearance of
CLINICAL APPLICATIONS IN
ddI is relatively high (85 or 210 mL/min using a cupro-
HEMODIALYZED PATIENTS
phan or a polysulfone membrane, respectively), with an
Figure 1 illustrates the molecular structure of the anti- extraction ratio of 40 to 60% during a four-hour dialysis
viral drugs. The following dosing recommendations of session and a FHD of 40%. In hemodialyzed patients, the
these drugs in hemodialysis patients proceed from the daily dose should be administered after the dialysis session
analysis of the existing pharmacokinetic studies, the to minimize drug loss [18]. This is consistent with the
methodologies of which are summarized in Table 1. Re- physicochemical and kinetic properties of the drug (mo-
nal abnormalities induced by antiretroviral drugs are lecular weight1000 D, and low protein-bound fraction
summarized in Table 2. and volume of distribution).
Zalcitabine. Zalcitabine (ddC) has a molecular weight
Nucleoside reverse transcriptase inhibitors of 211.22 D, a fraction bound to plasma protein less than
Protein binding of NRTIs is low. The free fraction 4% and a volume of distribution of 0.5 L/kg. Seventy to
of drug is unchanged. Drug metabolism is mediated by 75% of the dose of ddC is excreted unchanged in the
various cellular kinases and endogenous nucleotide tri- urine. Tubular secretion contributes significantly to uri-
phosphate pools [15]. Ten to 60% of NRTIs is usually nary elimination. The half-life of the parent drug is five-
excreted unchanged by the kidney. Thus, the unchanged fold higher than normal in patients with renal failure [19].
form and metabolites of accumulate in patients with re- The pharmacokinetics of ddC have not been studied in
nal insufficiency and may cause adverse effects. The dialysis patients. However, its dosage should be the same
lower a drug’s molecular weight, the more significant its as for patients with creatinine clearance below 10 mL/
removal by dialysis (Tables 3 and 4). min, and it should be administered after the hemodialysis
Zidovudine. Zidovudine (ZDV) has a molecular weight session to avoid any elimination in the dialysate (Table 5)
of 267.24 D, a fraction bound to plasma protein less than [20]. Indeed, the physicochemical and kinetic data (molecu-
38% and a volume of distribution of 1.5 L/kg. In patients lar weight 1000 D, low protein-bound fraction and vol-
with normal renal function, 15 to 20% of ZDV is excreted ume of distribution) suggest that ddC may be dialyzable.
unchanged by the kidney. Sixty to 75% of the drug recov- Stavudine. Stavudine (d4T) has a molecular weight of
ered in the urine consists of the pharmacologically inac- 224.22 D, a fraction bound to plasma protein less than
tive glucuronide metabolite (GZDV). Dosage adjust- 10%, and a volume of distribution of 0.5 to 1 L/kg. Forty
ment is necessary for patients with renal insufficiency percent of a dose of d4T is excreted unchanged in the
(Table 5). Hemodialysis has a minimal effect on ZDV urine by both glomerular filtration and tubular secretion
elimination but enhances GZDV elimination significantly [21]. As there are alterations in the pharmacokinetics of
(hemodialysis clearances of ZDV and GZDV using a d4T in patients with renal impairment, dosage adjust-
ment is necessary for these patients (Table 5). Hemodial-cuprophan membrane are 63 and 91 mL/min, respec-
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Fig. 1. Molecular structure of antiretroviral drugs.
ysis clearance of d4T is relatively high (120 mL/min), dialysis patients, the daily dose should be administered
after the dialysis session to avoid any drug loss. This iswith an extraction ratio of 68% during a four-hour hemo-
dialysis session on a nonspecified hemodialysis mem- consistent with the physicochemical and kinetic proper-
ties of the drug (molecular weight 1000 D, and lowbrane (abstract; Fiedler et al, J Am Soc Nephrol 207:
1059A, 1998). Since FHD has not been evaluated in hemo- protein bound fraction and volume of distribution).
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Table 1. Pharmacokinetic studies characteristics of antiretroviral drugs in hemodialyzed patients
Number Number of
Drug Ref. of studies patients S/M - dose - route Pharmacokinetics
Zidovudine [15, 40, 41, 42] 4 25 S - 200 mg - Oral
M - 100 mg tid - Oral ZDV: unchanged
M - 100 mg  4/day GZDV: T1⁄2  2 and AUC  10
M - 100 mg tid - Oral
Didanosine [17, 43] 2 24 S - 300 mg - Oral or IV T1⁄2  3 and AUC  7
Zalcitabine — — — —
Lamivudine [(Fiedler),a 23, 24] 3 8 M - 150 mg bid - Oral
S - 300 mg - Oral T1⁄2 increased and AUC  5
M - 150 mg bid - Oral
Stavudine (Fiedler)a 1 1 M - 30 mg bid - Oral T1⁄2  4 and AUC  4
Abacavir [26] 1 1 M - 300 mg daily - Oral Unchanged
Nevirapine [27] 1 1 M - 200 mg daily - Oral Unchanged
Delavirdine — — — —
Efavirenz [29] 1 1 M - 600 mg daily - Oral Unchanged
Ritonavir [32] 1 1 Rito.: M - 200 mg bid - Oral Rito.: Unchanged
Saquinavir [32] Saqui.: M - 600 mg bid - Oral Saqui.: T1⁄2  2 and AUC  5
Indinavir [(Fiedler),a 34, 35] 3 3 M - 800 mg tid - Oral Unchanged
Nelfinavir — — — —
Amprenavir — — — —
Abbreviations are: bid, twice daily; tid, thrice daily; S/M, single or multiple; HD, hemodialysis; T1⁄2, elimination half-life; AUC, area under the concentration-time
curve, ZDV, zidovudine; GZDV, zidovudine glucuromide; Rito, ritonavir; Saqui, saquinavir.
a Fiedler et al, J Am Soc Nephrol 207:1059A, 1998
Table 2. Renal abnormalities induced by antiretroviral drugs
Drug Abnormality
Nucleoside reverse transcriptase inhibitors
Zidovudine Lactic acidosis, rhabdomyolysis
Didanosine Lactic acidosis, elevated serum uric acid, magnesium, reverse elevation of plasma albumin in
a hemodialyzed patient
Zalcitabine Acute renal failure, lactic acidosis, hyponatremia, hypocalcemia, gut, renal calculi
Stavudine Lactic acidosis, plasma dysuric acid
Lamivudine Lactic acidosis
Abacavir —
Non-nucleoside reverse transcriptase inhibitors
Nevirapine Lactic acidosis
Delavirdine —
Efavirenz —
Protease inhibitors
Saquinavir Lactic acidosis, hypocalcemia, dys-kaliemia, magnesemia and phosphoremia, pancreatorenal
syndrome
Ritonavir Acute renal failure, pancreatorenal syndrome, hypocalcemia, dys-kaliemia, phosphoremia,
magnesemia and uricemia
Indinavir Lactic acidosis, intratubular precipitation, urinary lithiasis, renal insufficiency
Nelfinavir Lactic acidosis, hypocalcemia, dys-phosphoremia and uricemia, urinary lithiasis
Amprenavir —
Lamivudine. Lamivudine (3TC) has a molecular weight the daily dose should be administered after the dialysis
session to minimize drug loss. This is consistent withof 229.3 D, a fraction bound to plasma protein less than
36%, and a volume of distribution of 1.3 L/kg. Seventy the physicochemical and kinetic properties of the drug
(molecular weight1000 D, and low protein-bound frac-to 100% of each dose of 3TC is excreted unchanged in
the urine [22] by both glomerular filtration and tubular tion and volume of distribution).
One of our HIV-infected and hemodialyzed patientssecretion, with a threefold to fourfold increase in the
drug’s half-life in patients with renal impairment [23]. was treated for six months with normal doses of lamivu-
dine (150 mg every 12 hours), which resulted in excessiveTherefore, dosage adjustment is necessary for patients
with renal insufficiency (Table 5). Hemodialysis clear- drug accumulation but no side effects [25].
Abacavir. Abacavir (Aba) has a molecular weight ofance of lamivudine is by no means negligible (106 mL/
min) on a polysulfone membrane. Its extraction ratio is 670.76 D (sulfate), a fraction bound to plasma protein
less than 15%, and a volume of distribution of 0.8 to 1.953% [24] and FHD is 25%. In hemodialyzed patients,
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Table 3. Properties of nucleoside reverse transcriptase inhibitors affecting dialysis clearance
Properties
Molecular weight Protein binding Volume of distribution
Drug Daltons % L/kg Primary elimination pathway
Zidovudine 267.24 7–38 1.4–1.6 Hepatic metabolism
Didanosine 236.23 5 0.7–0.9 Renal excretion/hepatic metabolism
Zalcitabine 211.22 4 0.5–0.6 Renal excretion
Stavudine 224.22 10 0.5–1 Renal excretion/hepatic metabolism
Lamivudine 229.3 36 1.3 Renal excretion
Abacavir 670.76 10–13 0.8–1.9 Hepatic metabolism
(sulfate)
Table 4. Pharmacokinetic parameters of nucleoside reverse transcriptase inhibitors in subjects
with normal renal function and hemodialysis (HD) patients
Area under the
concentration-time curve
Elimination half-life hours mg·h/L Hemodialysis session 4 hours
% excreted
unchanged in Non-HD Non-HD Extraction ratio HD clearance FHD
Drug urine [45, 56] Normal day HD day Normal day HD day Membrane % mL/min %
Zidovudine 15–20 0.9–1.3 1.3–1.5 1.1 1.2–1.6 2.8–3.4 2.3–3.1 C 50–55 63 5–8
Didanosine 50–55 1.6 3.1 3.1 5.7 14 1.8–3.2 C, PS, PAN 40–60 85–210 40
Zalcitabine 70–75 2.2 10.7 — 18–34 93–189 — — 50 — —
Stavudine 35–50 1.3 5–8 — 1.9 6 — — 68 120 —
Lamivudine 70–100 5–9 13–20 13–17 13–18 60–104 60–100 PS 45–60 106 25
Abacavir 20 1.2 2.08 — 6 7.91 — PS 24 60–80 10
Membranes are: C, cuprophane; PS, polysulfone; PAN, polyacrylonitrile. FHD is hemodialysis clearance on total body clearance.
L/kg. Less than 20% of Aba is excreted unchanged in 60% and a volume of distribution of 1.3 L/kg. Less than
5% of the parent compound is excreted unchanged, andthe urine [26]. We studied the pharmacokinetics of Aba
in five HIV-infected patients who had various degrees 75 to 80% of each dose is recovered in the urine as the
of renal failure with creatinine clearance ranging from glucuronide metabolite. We studied the pharmacokinet-
60 to less than 10 mL/min [27]. No change was observed ics of nevirapine in two HIV-infected patients [28]. One
in the pharmacokinetics of Aba. Therefore, dosage ad- had a creatinine clearance of 60 mL/min and received
justment is not necessary for patients with renal insuffi- 200 mg of nevirapine twice daily. The other patient was
ciency (Table 5). In our patients, hemodialysis clearance hemodialyzed and received a single 200 mg dose of nevir-
of Aba and its extraction ratio on a polysulfone mem- apine. The pharmacokinetics of the drug were not sig-
brane are 80 mL/min and 24%, respectively. FHD is 10%, nificantly modified by the renal insufficiency. However,
and hemodialysis clearance is thus not clinically relevant the pharmacokinetics of the glucuronide metabolite have
despite physicochemical and kinetic properties, sug- not been studied. The hemodialysis clearance and extrac-
gesting a good dialyzability (molecular weight 1000 D, tion ratio on a polysulfone membrane of nevirapine were
and low protein-bound fraction and volume of distribu- 100.5 mL/min and 46.5%, respectively. FHD was 88%.
tion). Indeed, since hepatic metabolism of Aba is exten- This is consistent with the physicochemical and kinetic
sive, the fraction removed will not be clinically signifi- properties of the drug (molecular weight1000 D, weak
cant, and Aba may thus be administered regardless of protein-bound fraction and low volume of distribution).
the hemodialysis schedule. These results suggest that no dosage adjustment is neces-
sary in renal insufficiency, but that nevirapine should be
Non-nucleoside reverse transcriptase inhibitors administered after the dialysis session, to minimize drug
loss (Table 5).Except for nevirapine, protein binding of non-NRTIs
is higher than normal, and the free fractions of these drugs Delavirdine. Delavirdine has a molecular weight of
456.57 D, and a fraction bound to plasma protein up toare lower, in renal insufficiency (Tables 6 and 7). They
are primarily metabolized by the liver isoenzyme CYP3A4. 99%. Less than 5% of the drug is excreted unchanged
in the urine and about 51%, as the pharmacologicallyTheir excretion routes are both renal and biliary.
Nevirapine. Nevirapine has a molecular weight of inactive metabolite. The disposition of delavirdine in
renal failure and hemodialysis has not been studied.266.3 D, a fraction bound to plasma protein less than
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Table 5. Oral dosage recommendations for antiretroviral drugs in hemodialyzed patients
Drugs Normal dosage Hemodialyzed patients References
Nucleoside reverse transcriptase inhibitors
Zidovudineb 200 mg q 8 h 100 mg q 8 h [18, 44–47]
Didanosineb [18, 43, 44, 46]
BW 60 kg 200 mg q 12 h 100 mg q 24 h
BW 60kg 125 mg q 12 h 50 mg q 24 h
Zalcitabineb 0.75 mg q 8 h 0.75 mg q 24 h [18, 43–46]
Stavudineb [18, 43, 44, 46]
BW 60 kg 40 mg q 12h 20 mg q 24h
BW 60 kg 30 mg q 12 h 15 mg q 24 h
Lamivudineb 150 mg q 12 h 150 mg  1 [18, 43, 44, 46]
then 25–50 mg q 24 h
Abacavirb 600 mg q 12 h Normal dosage [25]
Non-nucleoside reverse transcriptase inhibitors
Nevirapineb 200 mg q 24 h 14 days Normal dosage [26]
then 200 mg q 12 h
Delavirdineb 400 mg q 8 h NA
Efavirenz 600 mg q 24 h Normal dosage [28]
Protease inhibitors
Saquinavir 600 mg q 8 h Normal dosagea [31, 45, 46]
Ritonavir 600 mg q 12 h Normal dosage [31, 45, 46]
Indinavir 800 mg q 8 h Normal dosage [33, 45, 46]
Nelfinavir 750 mg q 8 h Normal dosage [37, 45, 46]
Amprenavir 1200 mg q 12 h Normal dosage [37]
Abbreviations are: NA, not available; BW, body weight
a When saquinavir is used in combination with ritonavir, its dose should be reduced
b Drug should be administered after the hemodialysis session
Table 6. Properties of non-nucleoside reverse transcriptase schedule because of its extensive hepatic metabolism
inhibitors affecting dialysis clearance
(Table 5). This is consistent with the physicochemical
Properties and kinetic properties of the drug (molecular weight
Molecular Protein Volume of 1000 D, and high protein-bound fraction and volume
weight binding distribution Primary elimination of distribution).
Drug Daltons % L/kg pathway
Nevirapine 266.3 50–60 1.2–1.4 Hepatic metabolism Protease inhibitors
Delavirdine 456.57 99 — Hepatic metabolism
Protease inhibitors (PIs) are mainly metabolized byEfavirenz 315.68 99–100 30 Hepatic metabolism
the liver and in the gastrointestinal tract by CYP iso-
enzymes. Only a small percentage of these drugs is ex-
creted by the kidney. One of their main characteristics
is their high protein binding, predominantly to 1-acidSince more than 95% of the drug is predominantly me-
glycoprotein [31], except for indinavir. The pharmacoki-tabolized in the liver, no dosage adjustment should be
netic profiles of PIs suggest that renal function shouldnecessary for patients with renal insufficiency (Table 5).
not greatly affect the elimination of these drugs (TablesBecause hemodialysis removal of delavirdine has not
8 and 9).been studied, the drug should be administered after the
Ritonavir. Ritonavir has a molecular weight of 720.95hemodialysis session to avoid any potential elimination
D, a fraction bound to plasma protein greater than 98%,by the dialysis.
and a volume of distribution of 0.4 L/kg. Only 3 to 5%Efavirenz. Efavirenz has a molecular weight of 315.68
of a dose of ritonavir is excreted unchanged in the urine.D, a fraction bound to plasma protein up to 99 to 100%,
Since its renal clearance is negligible, a decrease in totaland a volume of distribution of 30 L/kg. Less than 1%
body clearance is not likely to occur in patients withof the efavirenz dose is excreted unchanged in the urine
renal insufficiency. Ritonavir is highly bound to protein.[29]. The disposition of efavirenz in renal impairment
Thus, hemodialysis is unlikely to remove a significanthas not been studied. However, no modification of its
amount of the drug [32]. We studied the pharmacokinet-pharmacokinetics should occur in these patients, because
ics of ritonavir in two HIV-infected patients [33]. Onemost of efavirenz is metabolized in the liver by CYP3A4.
had a creatinine clearance of 20 mL/min, and the otherSince its hemodialysis clearance and extraction ratio on
patient was hemodialyzed. Both of them received 400a polysulfone membrane are low (20 mL/min and 16%,
mg of ritonavir twice daily. The pharmacokinetics ofrespectively [30]) and despite that FHD is unknown, efavi-
renz may be administered regardless of the hemodialysis the drug were not significantly modified by the renal
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Table 7. Pharmacokinetic parameters of non-nucleoside reverse transcriptase inhibitors in subjects
with normal renal function and hemodialysis (HD) patients
Area under the
Elimination half-life concentration-time curve
hours mg·h/L Hemodialysis session
% excreted
unchanged in Non-HD Non-HD Extraction ratio HD clearance FHD
Drug urine [45, 46] Normal day HD day Normal day HD day Membrane % mL/min %
Nevirapine 3–5 25–30 21.8 19.2 — 254.4 142 PS 46.5 100.5 88
Delavirdine 5 4–11 — — — — — — — — —
Efavirenz 1 40–55 — 55 58 — 40 PS 16 20 —
Table 8. Properties of protease inhibitors affecting with a FHD of 4%. This is consistent with the physico-dialysis clearance
chemical and kinetic properties of the drug (molecular
Properties weight 1000 D, and high protein bound fraction and
Molecular Protein Volume of volume of distribution). These data suggest that no dos-
weight binding distribution Primary elimination age adjustment is necessary in renal insufficiency when
Drug Daltons % L/kg pathway
saquinavir is administered alone, but that the dosage
Ritonavir 720.95 98 0.4 Hepatic metabolism reduction should be performed when used in combina-
Saquinavir 766.95 98 3.6–10 Hepatic metabolism
tion with ritonavir. The drug can be administered regard-Indinavir 711.88 60 14 Hepatic metabolism
Nelfinavir 663.9 98 2–7 Hepatic metabolism less of the dialysis schedule (Table 5).
Amprenavir 507.65 90 16.4 Hepatic metabolism Indinavir. Indinavir has a molecular weight of 711.88
D, a fraction bound to plasma protein of 60%, and a
volume of distribution of 14 L/kg. Approximately 10%
of a dose of indinavir is recovered unchanged in the
insufficiency. Thus, in hemodialyzed patients, the phar- urine [34]. In patients with renal insufficiency, the phar-
macokinetic parameters of ritonavir are unchanged com- macokinetics of indinavir are not modified (abstract;
pared to those in patients with normal renal function. Fiedler et al, J Am Soc Nephrol 207:1059A, 1998) [35].
The hemodialysis clearance and extraction ratio of rito- In these studies, hemodialysis clearance and extraction
navir on a polysulfone membrane are 24 mL/min and ratio on a polysulfone membrane were very low, at 3
15.5%, respectively [32], with a FHD of 4%. This is consis- mL/min and 3%, respectively, much lower than those
tent with the physicochemical and kinetic properties of reported by Guardiola et al (185 	 7.2 mL/min) [36].
the drug (molecular weight 1000 D, and high protein However, our results and those of Fiedler were not unex-
bound fraction and volume of distribution). These data pected because they are consistent with the physicochemi-
suggest that no dosage adjustment is required for patients cal and kinetic properties of the drug (molecular weight
with renal insufficiency and that the drug can be adminis- 1000 D, and high protein bound fraction and volume
tered regardless of the dialysis schedule (Table 5). of distribution). Furthermore, FHD was almost 0% in
Saquinavir. Saquinavir has a molecular weight of our study. Therefore, indinavir can be administered to
766.95 D, a fraction bound to plasma protein greater patients with renal insufficiency at a normal dosage, irre-
than 98% and a volume of distribution of 3.6 and up to spective of their hemodialysis schedule (Table 5).
10 L/kg. Only 1 to 3% of a dose of saquinavir is excreted Nelfinavir. Nelfinavir has a molecular weight of 663.9
unchanged in the urine. Since renal clearance is negligi- D, a fraction bound to plasma protein greater than 98%,
ble, a decrease in total body clearance is not likely to and a volume of distribution of 2 to 7 L/kg.
occur in patients with renal insufficiency. Saquinavir is About 2% of nelfinavir is excreted unchanged in the
highly bound to protein. Thus, hemodialysis is unlikely urine, and its pharmacokinetics are not affected by renal
to remove a significant amount of the drug. We studied insufficiency. Furthermore, there are two observations
the pharmacokinetics of saquinavir in two HIV-infected of hemodialyzed patients who have been treated with
patients. One had a creatinine clearance of 20 mL/min, normal doses of nelfinavir (1500 to 2250 mg/day) for
and the other patient was hemodialyzed. Both of them three months and have not experienced any side-effects
received 600 mg of saquinavir twice daily. The pharmaco- [37] (abstract; Bhatti et al, 12th World AIDS Conference,
kinetics of the drug were significantly modified, but this Geneva, Switzerland 28 June through 3 July 1998, ab-
was related to the combination with ritonavir more than stract 60541). Therefore, dosage adjustment is not neces-
the alteration of the renal function. The hemodialysis sary for such patients (Table 5) [38]. While hemodialysis
clearance and extraction ratio of saquinavir on a polysul- clearance of nelfinavir has not been evaluated, the physi-
cochemical and kinetic data suggest that nelfinavir isfone membrane are 3.25 mL/min and 2%, respectively,
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Table 9. Pharmacokinetic parameters of protease inhibitors in subjects with normal renal function and hemodialysis (HD) patients
Area under the
Elimination half-life concentration-time curve
hours mg·h/L Hemodialysis session
% excreted
unchanged in Non-HD Non-HD Extraction ratio HD clearance FHD
Drug urine [45, 46] Normal day HD-day Normal day HD day Membrane % mL/min %
Saquinavir 1–3 7–13 12.72 9.72 — 109.16a 93.24a PS 2 3.25 4
Ritonavir 5 3–5 5.8 5.13 — 81.26a 60.72a PS 15.5 24 4
Indinavir 10–20 1.4–2.2 2.1 1.03 14–28 26.6 18.2 PS 3 3.25 almost 0
Nelfinavir 1–2 3.5–5 4 4 30 — — — — — —
Amprenavir 20 9 — — — — — — — — —
a Values for combination Ritonavir-Saquinavir treatment
Table 10. Side effects of antiretroviral therapies [44]
Drug Side effects
Nucleoside reverse transcriptase inhibitors
Zidovudine Gastrointestinal disorders, anemia, neutropenia, myopathy
Didanosine Diarrhea, nausea, pancreatitis, neuropathy
Zalcitabine Neuropathy, oral ulcerations
Stavudine Neuropathy
Lamivudine Well tolerated
Abacavir Hypersensitivity: forbids any re-introduction of the treatment
Non-nucleoside reverse transcriptase inhibitors
Nevirapine Rash, hepatitis
Delavirdine Headache, gastrointestinal disorders, rash
Efavirenz Dizziness, headache, insomnia, rash
Protease inhibitors
Saquinavir Nausea
Ritonavir Gastrointestinal disorders, hepatitis, hypertriglyceridemia, perioral paresthesia
Indinavir Urinary lithiasis, gastrointestinal disorders, hyperbilirubinemia
Nelfinavir Gastrointestinal disorders (diarrhea), rash
Amprenavir Gastrointestinal disorders, rash, headache, paresthesia
weakly dialyzable. Indeed, its molecular weight is less Second, simple and easy-to-apply recommendations
than 1000 D, but nelfinavir is highly bound to plasma should be established for the treatment of patients un-
protein and has a large volume of distribution (greater dergoing hemodialysis. These recommendations cannot
than 2 L/kg). be determined without a pharmacokinetic approach to
Amprenavir. Amprenavir has a molecular weight of the drug elimination during hemodialysis. We emphasize
507.65 D, a fraction bound to plasma protein of 90%, that except for ZVC and dianosine, more primary data
and a volume of distribution of 16.4 L/kg. A recent PI, are required on the pharmacokinetics of antiretroviral
its metabolism is primarily hepatic, and its renal elimina- drugs in patients with renal insufficiency.
tion is minimal. We have shown that the pharmacokinetics
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